The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

AML (Acute Myelogenous Leukemia) · AML

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, Beijing, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

AML (Acute Myelogenous Leukemia · Relapsed Acute Myelogenous Leukemia · Refractory Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Hangzhou, China

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Hematologic Malignancy · Acute Leukemia · Remission

Abroad (travel likely)RecruitingPHASE2

Minneapolis, United States

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

AML (Acute Myelogenous Leukemia)

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Acute Myeloid Leukemia · Pediatric AML

Abroad (travel likely)RecruitingEARLY_PHASE1

Houston, United States